Will Tesla Stock Go Up In 2026?
EV giant Tesla (NASDAQ:TSLA) has, somewhat surprisingly, undershot the broader…
Sell
47
IMVT Quote, Financials, Valuation and Earnings
Last price:
$26.62
Seasonality move
:
-17.71%
Day range:
$25.57 - $27.29
52-week range:
$12.72 - $28.08
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
8.77x
Volume:
3.6M
Avg. volume:
1.7M
1-year change:
-1.07%
Market cap:
$4.6B
Revenue:
--
EPS (TTM):
-$2.83
Analysts' Opinion
-
Consensus RatingImmunovant, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 10 Buy ratings, 5 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $39.47, Immunovant, Inc. has an estimated upside of 51.8% from its current price of $26.00.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $16.00 representing 38.46% downside risk from its current price of $26.00.
Fair Value
-
According to the consensus of 15 analysts, Immunovant, Inc. has 51.8% upside to fair value with a price target of $39.47 per share.
IMVT vs. S&P 500
-
Over the past 5 trading days, Immunovant, Inc. has overperformed the S&P 500 by 13.37% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Immunovant, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Immunovant, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Immunovant, Inc. reported revenues of --.
Earnings Growth
-
Immunovant, Inc. has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Immunovant, Inc. reported earnings per share of -$0.73.
Enterprise value:
4B
EV / Invested capital:
7.76x
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
-0.33x
EV / Free cash flow:
-9.36x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$420K
Return On Assets:
-78.54%
Net Income Margin (TTM):
--
Return On Equity:
-88.1%
Return On Invested Capital:
-88.09%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -$1.4M | -$291K | -$420K | -$89K | -$105K | |
| Operating Income | -$258.6M | -$352.5M | -$487.1M | -$115.7M | -$131.8M | |
| EBITDA | -$257.2M | -$352.2M | -$486.7M | -$115.7M | -$131.7M | |
| Diluted EPS | -$1.96 | -$2.22 | -$2.83 | -$0.75 | -$0.73 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $563.8M | $426.1M | $291.2M | $507.4M | $573.5M | |
| Total Assets | $566.7M | $428.1M | $292.1M | $515.7M | $583M | |
| Current Liabilities | $28.4M | $31.8M | $40.3M | $66.7M | $63.3M | |
| Total Liabilities | $30.3M | $32.4M | $40.3M | $66.7M | $63.3M | |
| Total Equity | $536.4M | $395.7M | $251.8M | $449.1M | $519.7M | |
| Total Debt | $2M | $614K | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$209.6M | -$271.6M | -$431M | -$88.6M | -$102.5M | |
| Cash From Investing | -$203K | -$659K | -$381K | -$196K | -- | |
| Cash From Financing | $71.9M | $472.8M | $480.6M | $730K | $24.6M | |
| Free Cash Flow | -$209.8M | -$272.3M | -$431.3M | -$88.8M | -$102.5M | |
IMVT
Sector
Market Cap
$4.6B
$28M
Price % of 52-Week High
92.59%
51.86%
Dividend Yield
0%
0%
Shareholder Yield
-17.08%
-1.4%
1-Year Price Total Return
-1.07%
-19%
Beta (5-Year)
0.557
0.518
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$24.06
200-day SMA
Buy
Level
$17.55
Bollinger Bands (100)
Buy
Level
15.11 - 22.37
Chaikin Money Flow
Sell
Level
-46M
20-day SMA
Buy
Level
$23.58
Relative Strength Index (RSI14)
Buy
Level
66.29
ADX Line
Buy
Level
22.75
Williams %R
Neutral
Level
-24.0657
50-day SMA
Buy
Level
$21.74
MACD (12, 26)
Buy
Level
0.84
25-day Aroon Oscillator
Buy
Level
96
On Balance Volume
Neutral
Level
33.6M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (21.9506)
Sell
CA Score
(Annual)
Level (-1.2838)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (8.979)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (2)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Immunovant, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling normal lives for patients with autoimmune diseases. It is developing a novel, fully human monoclonal antibody IMVT-1401 that selectively binds to and inhibits the neonatal fragment crystallizable receptor. The company was founded in 2018 and is headquartered in New York, NY.
Stock Forecast FAQ
In the current month, IMVT has received 10 Buy ratings 5 Hold ratings, and 0 Sell ratings. The IMVT average analyst price target in the past 3 months is $39.47.
-
Where Will Immunovant, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Immunovant, Inc. share price will rise to $39.47 per share over the next 12 months.
-
What Do Analysts Say About Immunovant, Inc.?
Analysts are divided on their view about Immunovant, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Immunovant, Inc. is a Sell and believe this share price will drop from its current level to $16.00.
-
What Is Immunovant, Inc.'s Price Target?
The price target for Immunovant, Inc. over the next 1-year time period is forecast to be $39.47 according to 15 Wall Street analysts, 10 of them rate the stock a Buy, 0 rate the stock a Sell, and 5 analysts rate the stock a Hold.
-
Is IMVT A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Immunovant, Inc. is a Buy. 10 of 15 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of IMVT?
You can purchase shares of Immunovant, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Immunovant, Inc. shares.
-
What Is The Immunovant, Inc. Share Price Today?
Immunovant, Inc. was last trading at $26.62 per share. This represents the most recent stock quote for Immunovant, Inc.. Yesterday, Immunovant, Inc. closed at $26.00 per share.
-
How To Buy Immunovant, Inc. Stock Online?
In order to purchase Immunovant, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get IMVT Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
IMVT
Sector
P/E ratio
--
24.31x
PEG ratio
-0.33x
-0.01x
P/B ratio
8.77x
1.83x
Price / LTM sales
--
1.60x
Growth Metrics
IMVT
Sector
Revenue growth
--
4.6%
Earnings growth
2.22%
10.88%
Revenue (5-year growth)
--
6.5%
Earnings forecast
-$0.73
-$0.20
Profitability
IMVT
Sector
Profitability FY 2024
-$377K
$3.5M
Return on invested capital
-88.09%
-31.66%
Return on assets
-78.54%
-27.84%
Return on equity
-88.1%
-37.28%
Earnings Date
Last Earnings Date
Nov
10
Next Earnings Date
Feb
5
Estimated Next Earnings Date
Feb
9
Balance Sheet
IMVT
Sector
Total cash
$521.9M
$26.8M
Short term investments
--
$26M
Total assets
$777.3M
$78.7M
Long term debt
--
$3.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
What Are the Best AI Power Stocks?
As the construction of AI infrastructure accelerates, the gap between…
Is IONQ The Best Quantum Stock to Buy?
Riding a wave of investor enthusiasm for the technology, quantum…
Stock Ideas
Sell
49
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 60x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
71
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
39
SMX alert for Dec 16
SMX (Security Matters) Plc [SMX] is down 18.2% over the past day.
Sell
33
ZBIO alert for Dec 16
Zenas BioPharma, Inc. [ZBIO] is up 13.35% over the past day.
Sell
38
HUT alert for Dec 16
Hut 8 Corp. [HUT] is up 3.92% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
